NCT07220252Phase 2, phase 3Recruiting

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

Study sponsor: TG Therapeutics, Inc. · TGTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-01-01Estimated

Enrollment · participants240Estimated

Source updated2026-09-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-08 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Relapsing Multiple Sclerosis

Treatments or interventions studied

UblituximabDrugAlso known as TG-1101, BRIUMVI
PlaceboDrug
PlaceboDrug
FingolimodDrug

Primary outcomes · main study measures

Read the study measures

measure: Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab; timeFrame: Predose and multiple timepoints up to Week 24; measure: Part A: Maximum Observed Concentration (Cmax) of Ublituximab; timeFrame: Day 1 and Day 15; measure: Part A: Participant B Cell Counts; timeFrame: Up to Week 24; measure: Part B: Annualized Relapse Rate (ARR); timeFrame: Up to 96 weeks; measure: Part C: Annualized Relapse Rate (ARR); timeFrame: Up to 168 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history